 |
| ||
| Join/Renew Contact ONS Terms of Use FAQ | |||
| HOME |  |
CNE Central | |
Clinical Practice | |
Membership | |
Patient Education | |
Publications | |
Research/PEP |
| About ONS |
| Shop, Join, Register |
| Career Center |
| Legislative Action Area |
| Global Affairs |
| Oncology News |
| Awards, Grants, Scholarships |
| Commercial Support |
| Newsroom |
| From the Editor |
|
ONS Profile |
Oncology News
New Cancer Drug Approvals/FDA Updates
In collaboration with the Food and Drug Administration, ONS provides its members with information about newly approved therapies for
patients with cancer via email. When such a communication is issued, ONS will immediately send an email indicating the nature of the
communication and provide a link to the full text of the communication. This will include information from the product label to
provide relevant clinical information on the indication, contraindications, dosing, and safety. Below is a list of all current
communications. ONS also maintains an archive of past communications.
| Date Sent | Manufacturer | Drug | Additional Information |
| December 24, 2008 | Ferring Pharmaceuticals Inc. |
Degarelix |
|
| December 19, 2008 | Novartis Pharmaceuticals |
Gleevec® |
|
| December 15, 2008 | Genzyme Corp. |
Mozobil™ |
|
| November 20, 2008 | GlaxoSmithKline Inc |
Promacta® |
|
| October 31, 2008 | Cephalon, Inc | TREANDA® | |
| October 15, 2008 | Eisai Medical Research | Ontak® | |
| September 26, 2008 | Eli Lilly and Company | Alimta® Injection | |
| September 19, 2008 | GE Healthcare | AdreView | |
| August 25, 2008 | Amgen Inc. | Nplate™ | |
| June 20, 2008 | Millennium Pharmaceuticals, Inc., The Takeda Oncology Company, and Johnson and Johnson Pharmaceutical Research and Development | Velcade® | |
| March 20, 2008 | Cephalon, Inc. | TREANDA® | |
| February 22, 2008 | Genentech, Inc. | Avastin® | |
| November 16, 2007 | Bayer Pharmaceuticals Corporation and Onyx Pharmaceuticals, Inc | NEXAVAR® | |
| November 8, 2007 | n/a | n/a | FDA Approved Boxed Warnings and other safety-related product labeling changes for the erythropoiesis-stimulating agents Epogen, Procrit, and Aranesp. |
| November 8, 2007 | Bristol-Myers Squibb | SPRYCEL™ | |
| October 29, 2007 | Novartis Pharmaceuticals Corp. | Tasigna® Capsules | |
| October 16, 2007 | Bristol-Myers Squibb | IXEMPRA™ | FDA approved ixabepilone injection for two indications |
| October 2, 2007 | ImClone Systems, Inc. | Erbitux® | Expanded labeling and granted regular approval |
| September 28, 2007 | Sanofi-Aventis | Taxotere® Injection Concentrate | |
| September 19, 2007 | Genzyme Corporation | Campath® | FDA expanded labeling and granted regular approval for single-agent alemtuzumab |
| September 17, 2007 | Genentech, Inc. | Avastin® | Warning and Dose and Administration for Non-Gastrointestinal Fistula Formation |
| September 13, 2007 | Lilly and Company | EVISTA® | |
| September 6, 2007 | TopoTarget | Totect™ |
If you are a member of ONS, and are not receiving these messages, you can adjust your email preferences by logging into your profile at https://profile.ons.org and then selecting "Preferences." If you do not have a profile, create one now.
Links
Overwhelmed by the amount of cancer news on the Internet? Try these links. The ONS website Editorial Board has reviewed them and found them to have excellent functionality and credibility.
Cancer Statistics 2006
Provided by the American Cancer Society
Cancer Treatment News
Provided by CancerConsultants.com
Major News Releases
Provided by the National Cancer Institute
Oncology Calendar
From continuing education programming to dates and deadlines related to certification, awards, grants, scholarships, and more, you'll find it all on this easy-to-use calendar.